We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CTEC:LSEConvaTec Group Plc Analysis

Data as of 2026-06-17 - not real-time

£205.20

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Convatec Group PLC is trading around £205, notably above its DCF‑derived fair value of roughly £147, indicating a material overvaluation. The stock’s trailing PE of 34.2 far exceeds the industry average of 24.6 and its price‑to‑book of 3.55 is also elevated, while the forward PE has collapsed to 12.2, reflecting improving earnings expectations. Technicals show a bearish trend with the 20‑day SMA (202) below the 50‑day SMA (213) and the price hovering just under the 200‑day SMA (230); however, the MACD histogram has turned positive and the RSI sits near the neutral 50, suggesting limited short‑term upside. Recent news highlighted a 5% price drop despite a “good start” to the year and 4.8% organic revenue growth, underscoring market sensitivity to guidance and cost‑inflation concerns from geopolitical tensions.
Fundamentally, the company delivers solid margins (gross 56%, operating 18%) and modest revenue growth (7.1% YoY), but carries a high debt load (≈£1.5 bn, debt‑to‑equity ≈ 100) against modest cash balances (£68 m) and no dividend, which limits income‑focused appeal. While analysts rate the stock as a strong‑buy, the combination of overvaluation, declining volume, and elevated volatility (≈32% 30‑day) warrants a cautious stance until price alignment with intrinsic value materialises.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Recent 5% price decline creates short‑term downside pressure
  • Technical indicators are mixed – bearish trend but bullish MACD histogram
  • Support level at £193 provides a modest floor

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Revenue growth and improving forward PE suggest earnings upside
  • High debt and low cash increase financial risk
  • Current price remains well above DCF fair value, limiting upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong operating margins and stable cash‑flow generation
  • Absence of dividend reduces total return appeal
  • Potential for price correction toward intrinsic value as market re‑prices valuation gaps

Key Metrics & Analysis

Financial Health

Revenue Growth7.10%
Profit Margin7.17%
P/E Ratio34.2
ROE10.91%
ROA7.02%
Debt/Equity100.00
P/B Ratio3.6
Op. Cash Flow£470.0M
Free Cash Flow£241.5M
Industry P/E24.6

Technical Analysis

TrendBearish
RSI49.7
Support£193.00
Resistance£216.60
MA 20£202.02
MA 50£212.67
MA 200£229.71
MACDBullish
VolumeDecreasing
Fear & Greed Index91.34

Valuation

Fair Value£146.57
Target Price£299.11
Upside/Downside45.76%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.31
Volatility32.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.